Logo Logo Logo Logo Logo
  • HOME
  • ABOUT
    • Management
    • Board of Directors
  • ADDICTION
    • Alcohol Addiction
    • Limitations of Current AUD Therapies
    • Our Proposed Solution
  • TECHNOLOGY
    • Overview
    • Phase 2b Clinical Trial Results
    • History of Ondansetron Use for AUD
    • Strengths and Competitive Advantages
  • Newsroom
    • Press Releases
    • Media
  • INVESTORS
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • CONTACT
  • HOME
  • ABOUT
    • Management
    • Board of Directors
  • ADDICTION
    • Alcohol Addiction
    • Limitations of Current AUD Therapies
    • Our Proposed Solution
  • TECHNOLOGY
    • Overview
    • Phase 2b Clinical Trial Results
    • History of Ondansetron Use for AUD
    • Strengths and Competitive Advantages
  • INVESTORS
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • CONTACT

Press Releases

Investor Relations

Investor Relations

  • Overview
  • Analyst Coverage
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance

Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland

Jan 9, 2020

Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries

Dec 19, 2019

Adial Pharmaceuticals Receives Notice of Allowance of Additional Patent for the Treatment of Alcohol Use Disorder with AD04 in Patients Identified Using a Molecular Genetic Biomarker

Dec 16, 2019

Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial

Dec 13, 2019

Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites

Oct 29, 2019

Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker

Oct 17, 2019

Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

Oct 7, 2019

Adial Files Clinical Trial Application to Commence Phase 3 Trial

Oct 1, 2019

Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

Sep 25, 2019

Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

Sep 11, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...11

    ©Adial Pharmaceuticals 2021